Page 8 - Synlogic Inc News Today

CAMBRIDGE, Mass., Jan. 24, 2023 -- Synlogic, Inc. , the leading company advancing therapeutics based on synthetic biology, today announced it will participate in the following upcoming... | January 24, 2023

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU) - read this article along with other careers information, tips and advice on BioSpace

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology,...

/PRNewswire/ -- The microbiomes market is forecasted to grow by USD 891.94 million from 2022 to 2027. Moreover, the growth momentum will accelerate at a CAGR...

/PRNewswire/ -- The microbiomes market is forecasted to grow by USD 891.94 million from 2022 to 2027. Moreover, the growth momentum will accelerate at a CAGR...

Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria...

Investegate announcements from NMD Pharma, Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors

Mike Heffernan appointed Chairman of NMD Pharma's Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has overseen

/PRNewswire/ -- The "Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (FMT...

/PRNewswire/ -- The "Crohns Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis" report has been added to ResearchAndMarkets.coms...